• Hepion Pharmaceuticals reported simulation results showing its GV104 buccal film prevented all modeled fentanyl-induced cardiac arrests when taken before exposure.
• FDA feedback supported the modeling approach but called for revisions to strengthen evidence of long-term preventive protection.
• The predicted protection could change following revisions; GV104 targets military personnel and first responders at risk of opioid exposure.
• Remaining work before a regulatory filing centers on manufacturing, with commercial-scale registration batch production planned for 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hepion Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202610260801ACCESSWRNAPR_____1241481) on October 26, 2026, and is solely responsible for the information contained therein.